Online Only Articles

Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response

Department of Medicine, Section of Hematology, University of Verona, Italy
Padua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy
Hematology Unit, Dell’Angelo Hospital, Venezia-Mestre, Italy
Hematology Unit, Ca’ Foncello Hospital, Treviso, Italy
Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy
Department of Medicine, Section of Hematology, University of Verona, Italy
Padua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy
Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy
Department of Medicine, Section of Hematology, University of Verona, Italy
Padua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy
Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy
Department of Medicine, Section of Hematology, University of Verona, Italy
Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy
Vol. 100 No. 8 (2015): August, 2015 https://doi.org/10.3324/haematol.2015.124685